- Conditions
- Neuroblastoma, Neuroendocrine Tumor
- Interventions
- Retinoic Acid, Placebo
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 6 Months to 30 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- ACTH, Cushing's Syndrome
- Interventions
- DOTATATE PET-CT, F-DOPA PET CT, CT scan, Routine MRI scan, Gated MRI scan, 68Ga-DOTATATE, 18F-DOPA
- Radiation · Diagnostic Test · Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma, Pheochromocytoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- 90Y-DOTA-tyr3-OCTREOTIDE
- Radiation
- Lead sponsor
- O'Dorisio, M S
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Diabetic Retinopathy
- Interventions
- Octreotide Acetate in Microspheres, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Gastrointestinal Bleeding
- Interventions
- Octreotide LAR Depot
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Neuroendocrine Tumors
- Interventions
- Data collection
- Other
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 8
- States / cities
- Tampa, Florida • Wichita, Kansas • New Orleans, Louisiana + 5 more
- Conditions
- Acromegaly
- Interventions
- Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 4
- States / cities
- Ann Arbor, Michigan • Portland, Oregon • Dallas, Texas + 1 more
- Conditions
- Acromegaly
- Interventions
- Octreotide
- Drug
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Chicago, Illinois • Baltimore, Maryland + 3 more
- Conditions
- Acromegaly
- Interventions
- Pegvisomant, Sandostatin LAR
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 8 more
- Conditions
- Acromegaly
- Interventions
- Octreotide Implant, Sandostatin LAR Depot
- Drug
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 8
- States / cities
- Palo Alto, California • Denver, Colorado • Miami, Florida + 5 more
- Conditions
- Anal Cancer, Colorectal Cancer, Drug/Agent Toxicity by Tissue/Organ, Radiation Enteritis
- Interventions
- octreotide acetate, Placebo
- Drug · Other
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 112
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Chico, California + 89 more
- Conditions
- Acromegaly
- Interventions
- Debio 4126, Placebo
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 7 more
- Conditions
- Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor, Pancreatic Gastrinoma, Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2, Pancreatic Vipoma
- Interventions
- Bevacizumab, Everolimus, Octreotide Acetate
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 388
- States / cities
- Mobile, Alabama • Anaheim, California • Antioch, California + 272 more
- Conditions
- Colorectal Cancer, Diarrhea
- Interventions
- irinotecan hydrochloride, octreotide acetate
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 2
- States / cities
- East Hanover, New Jersey • Princeton, New Jersey
- Conditions
- Acromegaly
- Interventions
- Octreotide capsules
- Drug
- Lead sponsor
- Chiasma, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more
- Conditions
- Healthy
- Interventions
- Octreotide 1 MG/ML
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor
- Interventions
- Paltusotine, Placebo
- Drug
- Lead sponsor
- Crinetics Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 17
- States / cities
- Gilbert, Arizona • Newport Beach, California • New Haven, Connecticut + 14 more
- Conditions
- Acromegaly
- Interventions
- Pasireotide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Ann Arbor, Michigan • New York, New York
- Conditions
- Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2
- Interventions
- Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate, Recombinant Interferon Alfa-2b
- Biological · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 427 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2027
- U.S. locations
- 493
- States / cities
- Mobile, Alabama • Fairbanks, Alaska • Fort Smith, Arkansas + 321 more
- Conditions
- Colorectal Cancer, Diarrhea
- Interventions
- loperamide hydrochloride, octreotide acetate
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 33
- States / cities
- La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more
- Conditions
- Hyperglucagonemia, Obesity
- Interventions
- Glucagon, Octreotide, Placebo, Insulin
- Drug · Behavioral
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Octreotide, Sputum
- Interventions
- Octreotide
- Drug
- Lead sponsor
- Danbury Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Danbury, Connecticut
- Conditions
- Acromegaly
- Interventions
- Octreotide capsules
- Drug
- Lead sponsor
- Chiasma, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Acromegaly, Pituitary Neoplasm
- Interventions
- Sandostatin LAR Depot versus transsphenoidal surgery
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland